RxDoctor Payments Data

Gladelynn Adlao

Registered Nurse · Glendora, CANPI 1881012193

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 66.3% of it on its own, with 3 other manufacturers making up the rest. Among registered nurse clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,690in general payments, 2019–2025

Across 26 payments — averaging $103.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Neurocrine Biosciences, Inc.$476
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$330
  • Acadia Pharmaceuticals Inc$101

What the payments were for

  • Food & beverage$2,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,690 in reported general payments places this provider in the 95th percentile of 533 registered nurse providers in California.

See all registered nurse providers in California

Medicare billing

Part B allowed, 2024
$213,544
Medicare patients
481
Services billed
2,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate22$78,789
EliquisApixaban37$23,479
Metformin Er GastricMetformin Hcl44$21,470
JardianceEmpagliflozin31$18,427
JanuviaSitagliptin Phosphate22$11,956
FarxigaDapagliflozin Propanediol14$8,431
Divalproex Sodium187$7,672
Olanzapine205$7,512
Fenofibrate11$7,378
XareltoRivaroxaban11$6,634
TradjentaLinagliptin11$5,743
Quetiapine Fumarate139$3,744
Risperidone180$3,426
Haloperidol79$3,138
Benztropine Mesylate154$2,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$1,783$85,42433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 533 registered nurse providers in California.

Other registered nurse in Glendora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →